Macsart

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Macsart

Understanding Macsart

Macsart is a medication categorized as an angiotensin II receptor blocker (ARB). It is primarily used in the management of cardiovascular conditions, specifically to address high blood pressure (hypertension).

Mechanism of Action

The active component in Macsart works by targeting a specific hormone in the body known as angiotensin II. This hormone naturally causes blood vessels to narrow or constrict. By blocking the receptors for this hormone, the medication allows blood vessels to remain relaxed and widened.

This physiological change results in:

  • Reduced pressure within the vascular system
  • Improved blood flow
  • Decreased workload on the heart muscle

Primary Use

Macsart is utilized to help control long-term high blood pressure. Maintaining blood pressure within a standard range is a preventative measure used to reduce the risk of more severe cardiovascular events, such as strokes or heart attacks. It is often used as a long-term maintenance therapy for individuals whose blood pressure requires pharmacological intervention to remain stable.

Regulatory References

  1. U.S. National Library of Medicine
  2. MedlinePlus

What side effects are possible with Macsart?

Possible Side Effects and Safety Information: Macsart

Macsart (Telmisartan) is an Angiotensin II Receptor Blocker (ARB) with an established safety profile based on regulatory documents. The most frequently reported adverse reactions from clinical trials for hypertension typically fall into the Common frequency category (ge 1% incidence) and include back pain, sinusitis or sinus inflammation, and diarrhea. Other commonly observed reactions include dizziness, headache, fatigue, and upper respiratory tract infections.

Serious and Clinically Significant Adverse Reactions

Macsart carries a serious risk of Fetal Toxicity and is contraindicated during the second and third trimesters of pregnancy due to the high risk of injury and death to the developing fetus. Use must be discontinued immediately upon detection of pregnancy. Clinically significant, though less frequent, adverse events documented in official regulatory labeling include angioedema (a potentially serious allergic reaction involving swelling of the face, lips, or tongue) and hypotension (low blood pressure), especially in patients who are volume- or salt-depleted. There is also a risk of hyperkalemia (elevated potassium levels), requiring caution and periodic monitoring of serum electrolytes in at-risk populations, such as those with renal impairment or those taking potassium-sparing medications.

Population-Specific Restrictions

Macsart is contraindicated in patients with a history of hypersensitivity to the drug, in pregnant women beyond the first trimester, and in patients with severe hepatic impairment (biliary obstruction or cholestasis). Caution is advised in patients with advanced renal impairment, bilateral renal artery stenosis, or in geriatric populations who may be more susceptible to the hypotensive effects.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Macsart (Telmisartan) overdose is derived exclusively from official regulatory documentation and outlines the documented clinical manifestations and required emergency actions.

Documented Overdose Manifestations and Risks

Feature Official Regulatory Statement
Documented Manifestations The most prominent reported clinical manifestations are hypotension (excessively low blood pressure) and tachycardia (fast heart rate); bradycardia (slow heart rate) has also been noted.
Severe Outcomes The severe consequences of overdose may include profound hypotension leading to shock and the risk of acute renal failure.
Antidote Information No specific antidote is known for a telmisartan overdose. The compound is not removable by hemodialysis.

When to Seek Immediate Medical Help

If an overdose is suspected, immediate medical attention must be sought, as per official guidance. Management is strictly symptomatic and supportive. For severe hypotension, the mandated initial action is placing the patient in the supine position (lying flat on the back), potentially followed by an intravenous infusion of normal saline for fluid and salt replacement. Infants with a history of in utero exposure should be closely observed for hypotension, oliguria, and hyperkalemia.

Therapeutic Uses of Macsart

What Macsart Treats: Main Uses and Benefits

The use of Macsart is relevant for supportive treatment across domains involving cardiovascular health and symptoms related to systemic imbalance due to high blood pressure. The medicine is commonly used to help manage the condition of essential hypertension. It is considered relevant in managing risks for high-risk adult patients and assists with symptomatic management in related conditions like heart failure.

This medicine is applied across clinical settings that involve heightened systemic burden, and is used across conditions characterized by periods of persistent high blood pressure and associated complications. Macsart is commonly used to help with the stabilization of blood pressure and may assist in the management of cardiovascular health risks and support for heart and kidney health. It is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.

“This medicine is commonly used to help with the stabilization of blood pressure, which may assist with maintaining functional stability.”


Quick Fact: Relevant for Managing Systemic Strain

Macsart is applied when symptoms create noticeable physiological strain on the circulatory system, and is applied in situations where additional symptomatic support is needed to address potential issues that may arise from chronic high pressure.

Eligibility and Restrictions for Use

Macsart (Telmisartan) eligibility is defined by official regulatory documentation, primarily allowing use in the adult population.

Populations for Whom Use is Contraindicated

Use of Macsart is strictly prohibited (contraindicated) for the following groups:

  • Patients with known hypersensitivity to Telmisartan or any tablet component.
  • During the second and third trimesters of pregnancy (requires immediate discontinuation upon detection of pregnancy).
  • Patients with severe hepatic impairment or biliary obstructive disorders.
  • Patients with diabetes mellitus who are concurrently taking a medicine containing Aliskiren.

Age and Comorbidity Restrictions

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years; use is not recommended.
  • Liver Function: Patients with mild to moderate hepatic impairment require caution, and dosage must not exceed 40 mg once daily (Source: EMA/equivalent). Severe impairment is a contraindication.
  • Kidney Function: Use in severe renal impairment or in patients on hemodialysis requires caution and close monitoring. Patients with volume or salt depletion must have their condition corrected before starting therapy.
  • Lactation: It is recommended that nursing be discontinued or the drug be discontinued.

What should I know about interactions with other medicines?

Macsart Interactions with other medicines and products

Official regulatory documents define specific restrictions and requirements for combining Macsart (Telmisartan) with other products. Co-administration of Aliskiren is prohibited in patients with diabetes mellitus and is formally avoided in patients with renal impairment (GFR <60 mL/min/1.73 m2). This represents a formal contraindication against dual blockade of the Renin-Angiotensin System (RAS) in high-risk patients.

Documented Interaction Patterns

Interacting Agent Official Outcome (Regulatory Language)
ACE Inhibitors or Aliskiren Dual blockade of the RAS, associated with increased risks of hypotension and hyperkalemia; combined use is generally avoided.
NSAIDs Increased risk of renal impairment and a documented loss of antihypertensive effect.
Digoxin Telmisartan increases Digoxin plasma concentrations (median Cmax increase of 49%); Digoxin levels must be monitored when therapy is adjusted.
Lithium Co-administration may increase lithium blood levels, raising the risk of toxicity.
Potassium-Raising Agents Concomitant use with potassium-sparing diuretics or potassium supplements/salt substitutes increases the risk of hyperkalemia.
Alcohol (Ethanol) May have additive effects in lowering blood pressure.
OATP1B1 Substrates (e.g., Atogepant, Atorvastatin) Telmisartan acts as an OATP1B1 inhibitor, which increases the systemic exposure of these co-administered drugs.

Mechanism of Action

Telmisartan functions as an Angiotensin II Receptor Blocker (ARB) by binding selectively and non-competitively to the Angiotensin II Type 1 ( AT1) receptors in tissues such as vascular smooth muscle and the adrenal gland. This interaction antagonizes the binding of Angiotensin II, the primary pressor agent of the Renin-Angiotensin-Aldosterone System (RAAS).

Blocking the AT1 receptor disrupts the intracellular signaling cascade responsible for inducing vasoconstriction and elevating systemic vascular resistance. This inhibition also reduces the Angiotensin II-mediated stimulation of aldosterone release from the adrenal cortex.

The resulting physiological effects include the modulation of peripheral resistance through vasodilation and an alteration in fluid balance due to reduced aldosterone levels. These two mechanisms—decreased vascular tone and reduced sodium/water reabsorption—lead to a reduction in blood pressure and overall fluid volume, decreasing cardiac preload.

Dosage and Administration Information

How to Use Macsart (Telmisartan)

Macsart (telmisartan) is a medication administered orally once daily. Adherence to specific administration conditions and established dosing schedules is required for proper use.


Dosing and Frequency

Macsart tablets are available in 20 mg, 40 mg, and 80 mg strengths. The dosing regimen is standardized based on the indication:

Use Case Usual Starting Dose Maximum Daily Dose
Hypertension 40 mg once daily 80 mg once daily
Cardiovascular Risk Reduction 80 mg once daily 80 mg once daily

Most of the intended effect is observed within two weeks, with the maximum effect generally achieved after four weeks of treatment. The dose is typically adjusted by a healthcare provider after this period, if necessary.


Administration Conditions and Handling

The following instructions govern the practical use of the tablet, regardless of the dose:

  • Timing: The tablet is taken once daily with liquid, at the same time each day.
  • Food Intake: Macsart may be administered with or without food.
  • Preparation: The tablet must be kept in its sealed blister or container and should be removed immediately before administration to protect it from moisture. Do not crush, chew, or cut the tablet.

Population-Specific Use Rules

Dosage adjustments are noted for certain patient groups:

  • Hepatic Impairment: For patients with mild to moderate liver impairment, the total daily dose should not exceed 40 mg.
  • Elderly Patients: No initial dosage adjustment is necessary for older adults.
  • Missed Dose: If a dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence for Macsart: Overview of Clinical Studies

Evidence for Use in Managing Essential Hypertension

Research has examined measurements related to blood pressure in adults who have essential hypertension (high blood pressure). These investigations mainly rely on short-term Randomized Controlled Trials (RCTs) and controlled comparative studies, where the medicine was observed in how it affected blood pressure levels. Researchers focused on tracking changes in both systolic and diastolic blood pressure (BP), including monitoring over a full 24-hour period using Ambulatory Blood Pressure Monitoring (ABPM). The majority of the trials used to establish these initial BP patterns were of a short-term duration, meaning that research exploring long-term data in maintaining blood pressure levels over many years is not fully established by these specific short-term studies.


Evidence for Cardiovascular Risk Reduction in High-Risk Adults

The evidence base for Telmisartan was studied in cohorts where severe health outcomes were tracked over extended observation periods. This research primarily involved large-scale, international, long-term clinical outcome trials that tracked thousands of participants, including high-risk adults with established vascular disease or Type 2 diabetes. These studies research examined a primary outcome called Major Adverse Cardiac Events (MACE), which tracked the frequency of serious issues like cardiovascular death, non-fatal myocardial infarction, and stroke.

Comparative evidence is lacking from trials that directly examine Telmisartan against all other individual Angiotensin II Receptor Blockers (ARBs) specifically for MACE reduction. Furthermore, the populations in these large outcome trials were carefully selected, meaning that data for certain groups remain insufficient, such as those with specific types of severe heart failure.


Studies Assessing Support for Kidney Health Outcomes

The research examined measurements of physiological strain or stress on the kidneys, particularly in cohorts of hypertensive patients who also have Type 2 diabetes. Research examined key biomarkers of kidney strain, such as changes in the level of protein found in the urine (proteinuria and microalbuminuria). However, the evidence is largely based on these changes in intermediate biomarkers. Long-term effects are not fully established regarding hard clinical endpoints, such as the actual rate of kidney function decline or the long-term need for interventions like dialysis.

Key Studies & References

  1. The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) - Study Details
  2. Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) - Clinical Summary
  3. Telmisartan versus angiotensin-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials
  4. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension

Frequently Asked Questions (FAQ)

Common questions about Macsart (FAQ)


Q: Can Macsart cause an increase in potassium levels in the blood (hyperkalemia)?

A: According to official drug labeling, hyperkalemia (high potassium levels) is documented as a possible, clinically significant adverse reaction. Monitoring of serum electrolytes is typically expected in patients considered to be at risk, as per official documentation.


Q: Is it true that Macsart can cause the face, lips, or throat to swell (angioedema)?

A: Official regulatory documents indicate that angioedema, which is the swelling of the face, lips, or throat, is a documented adverse reaction. This reaction is considered rare but serious and potentially life-threatening.


Q: What kind of monitoring (blood tests) is usually needed when taking Macsart?

A: The official labeling indicates that periodic monitoring of specific blood values is typically required. These checks commonly include measurements of serum creatinine and serum potassium levels.


Q: Is dizziness or feeling lightheaded a common side effect of Macsart?

A: Yes, official product information lists dizziness as a common adverse reaction, meaning it was reported in ge 1% of patients during clinical trials. This effect is often related to the medicine's role in lowering blood pressure.


Q: What is the main difference between Macsart (an ARB) and an ACE inhibitor?

A: Macsart is classified as an Angiotensin II Receptor Blocker (ARB), which works by directly blocking the AT1 receptor. Unlike ACE inhibitors, this mechanism does not involve the breakdown of the chemical bradykinin, which has been linked to the side effect of a persistent cough.


Q: Can Macsart be taken if a patient developed a persistent cough on a different blood pressure medicine?

A: Regulatory documents do not list a persistent cough as a frequently reported side effect for Macsart. The difference in the drug's mechanism of action compared to ACE inhibitors is the reason for this distinction.


Q: What are the most frequently reported side effects listed for Macsart?

A: Based on clinical trial data, the most frequently reported adverse reactions (ge 1% incidence) include back pain, sinusitis (sinus inflammation), and diarrhea. Dizziness and fatigue are also commonly observed reactions.


Q: Is it safe to take ibuprofen (NSAID painkiller) while on Macsart?

A: Co-administration with NSAIDs like ibuprofen is officially documented as presenting an increased risk of renal impairment (strain on the kidneys). It can also cause a reduction in the blood pressure lowering effect of Macsart.


Q: Does alcohol consumption interact with the effects of Macsart?

A: Official labeling states that alcohol (ethanol) may have additive effects in lowering blood pressure when consumed concurrently with Macsart. This can potentially increase the risk of low blood pressure symptoms.


Q: What were the key findings from the major clinical studies on Macsart?

A: Major clinical studies primarily focused on high-risk patients and examined the reduction of cardiovascular events (MACE). Studies observed evidence suggesting a reduction in the occurrence of serious cardiovascular events, including cardiovascular death and non-fatal myocardial infarction.


Q: Is it true that Macsart is usually a long-term or life-long medication?

A: Official product information confirms that Macsart is intended for the management of chronic conditions such as systemic hypertension and cardiovascular risk reduction. Such therapeutic goals typically require continuous, long-term therapy.


Q: Can Macsart be used by patients with diabetes?

A: Official labeling specifies that Macsart is strictly contraindicated (prohibited) for patients with diabetes mellitus who are concurrently taking a medicine containing Aliskiren.


Q: Does Macsart have different effects on the body compared to other ARB medicines?

A: Clinical pharmacology documents describe Macsart as having a high binding affinity and a slow dissociation rate from the AT1 receptor. These pharmacological properties are considered a key differentiating feature within its class.


Q: Can Macsart cause back pain or muscle cramps?

A: Back pain is listed as a common adverse reaction (ge 1% incidence) in the official documents. However, muscle cramps are not listed among the most frequently reported side effects.


Q: Can I use salt substitutes that contain potassium while taking Macsart?

A: Official drug interaction warnings indicate that combining Macsart with potassium supplements or salt substitutes that contain potassium may increase the risk of developing hyperkalemia (high potassium levels).


Q: Does the official research mention if Macsart helps prevent stroke or heart attack?

A: Official research focused on examining the effect of Macsart on reducing the risk of a combined endpoint that includes events such as stroke and non-fatal myocardial infarction (heart attack).


Q: How can a patient generally tell if Macsart is working for them?

A: Macsart's primary goal is to help maintain arterial blood pressure within a healthier range. Therefore, blood pressure measurement is the primary measure targeted by the medicine's therapeutic goal.


Q: What is Macsart used for besides just high blood pressure?

A: In addition to the management of essential hypertension, Macsart is officially indicated for cardiovascular risk reduction. This use is targeted at high-risk adults who already have established vascular disease or Type 2 diabetes.


Q: Is Macsart the same type of medicine as a diuretic or a water pill?

A: Macsart is classified as an Angiotensin II Receptor Blocker (ARB), not a diuretic (or water pill). While it affects fluid balance indirectly, its core mechanism is to relax blood vessels. Some commercial versions of Macsart may be combined with a diuretic.


Q: Does official information state that Macsart helps with kidney protection?

A: Official research has examined the effects of Macsart on biomarkers associated with kidney strain, such as changes in the level of protein in the urine. These studies focus on examining the effects on kidney function markers.


Q: Is Macsart better to take in the morning or at night?

A: Regulatory documents state the medicine should be taken once daily at the same time each day. The prolonged half-life is intended to support a 24-hour effect.


Q: Why do some people use Macsart even if their blood pressure is not high?

A: Macsart is officially indicated for cardiovascular risk reduction in adults who have established vascular disease or Type 2 diabetes. In these specific high-risk populations, the medicine is used to lower the chances of a serious event, even if blood pressure is already controlled.


Q: Is there a known allergy warning or ingredient people should look out for in Macsart?

A: Official labeling states that Macsart is strictly contraindicated (prohibited) in patients with a known history of hypersensitivity to Telmisartan or any component of the tablet.


Q: What is the typical timeline for checking blood pressure after starting Macsart?

A: Clinical studies indicate that the maximum blood pressure lowering effect is generally achieved after four weeks of treatment. A review or adjustment of the dose is typically considered after this period.


Q: Do I need to be careful when moving from a sitting to a standing position while on Macsart?

A: Because of the potential risk of hypotension (low blood pressure), the effects of Macsart may be associated with symptoms like dizziness when changing posture too quickly.


Q: What is meant by the phrase “renoprotection” in studies about Macsart?

A: Renoprotection is a term used in medical studies to refer to the medicine's studied effects on biomarkers that indicate strain or stress on the kidneys. This includes changes in markers like protein found in the urine.


Q: Can a patient get an allergic reaction to Macsart even if they took it before?

A: Official documentation warns against use in patients with a known history of hypersensitivity (allergic reaction) to the drug, which includes severe allergic reactions such as angioedema.

How should Macsart be stored and disposed of?

Storage and Handling Instructions

Macsart (Telmisartan) tablets require strict conditions due to their hygroscopic nature. The product must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from moisture and excessive heat.

Requirement Official Instruction
Packaging Keep in the original sealed blister pack; do not remove the tablet until immediately before use.
Child Safety Keep out of the reach of children.

Disposal Requirements

Unused or expired Macsart must be disposed of in accordance with local regulations, such as utilizing a drug take-back program. The medicine must not be flushed down a toilet or sink, or otherwise released into the wastewater system, as the compound is restricted from entering the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Macsart found in:

A-Z Index: